3 Reasons Why This Vaccine Maker May Dominate the European Market
The European market is a major one for vaccine makers. First of all, more than 448 million people live in the European Union. At about $20 per dose for a two-dose vaccine, that represents a nearly $18 billion opportunity.
And second, the region has struggled through a vaccine shortage. Today, only 33% of the EU population have received at least one dose of a coronavirus vaccine. That means a lot of people still need vaccination.
Which company may benefit most? None other than pharmaceutical giant Pfizer (NYSE: PFE). The company just landed a massive deal with the European Commission. It will deliver 900 million vaccine doses from later this year through 2023. This is in addition to the commission's initial order for 600 million doses. These orders offer Pfizer an immediate advantage -- it has the opportunity to build a relationship with the European Union, and to show the strengths of its vaccine.
Source Fool.com
